RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Novo-Nordisk (NVO)

NYSE:NVO

Novo-Nordisk (NVO)

47.41
-0.01 (0.02%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
265 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 30 opinions in the last 12 months.

Novo Nordisk (NVO) is facing significant challenges as competition in the weight-loss pharmaceutical market intensifies, particularly from Eli Lilly (LLY). Several experts expressed concerns over NVO's declining market share and weaker growth expectations due to pressure from LLY's strong positioning and marketing efforts. Reviews indicate that while NVO has potential long-term growth, particularly in diabetes care and weight management, its performance is currently hindered by a negative technical outlook and a series of disappointing earnings reports. The company’s reliance on a few key products has led to a perception of it being a 'one-trick pony,' and many analysts are advising caution or recommend waiting for more favorable conditions before considering an investment. Overall, while the long-term outlook could improve, the short-term pressures are prompting skepticism among analysts.

consensus icon
Consensus
Negative
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY

Novo-Nordisk(NVO)

Jun 17, 2022
Likes company and has owned shares for a long time. #1 company in European diabetic market. Share prices are a little over priced. Will continue holding shares for the long term.
Photo of Darren SissonsDarren Sissons
Owned
Unlock Rating
$105.58

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Novo-Nordisk(NVO)

May 12, 2022
NVO vs. LLY Focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$104.48

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Feb 04, 2022
(A Top Pick Feb 10/21, Up 46%) Believes company is leading insulin producer for diabetics. Revenues outside USA are increasing. Above average financial results from previous quarter was rewarded by market. Rising diabetes levels in society will be good for company. Company has very little debt and is looking at other products.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$99.67

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novo-Nordisk(NVO)

Jan 17, 2022
He was negative on this 5 years ago but now likes it and owns some for the long term. Insulin prices have normalized and it has a good weight loss drug. When asked to compare to Lilly he prefers NVO although Lilly is good too. The only concern is that this is a defensive growth stock and some might sell to buy cyclicals.
Photo of David FingoldDavid Fingold
Owned
Unlock Rating
$96.32

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Oct 08, 2021
(A Top Pick Feb 10/21, Up 49%) Leading company for making insulin. The FDA approved their 2.5mg dose of weight-loss drug, which helped share prices. They are first to market with it. The expectations for earnings were moved higher. Getting more international sales in the long term. Stock is starting to get noticed by fund managers internationally.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$98.38

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Aug 31, 2021
A Danish drug company that makes insulin. He likes the pharma stocks, though have been underperforming. He owns many pharmas, but you can't own all of them.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$100.38

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Novo-Nordisk(NVO)

Jun 17, 2021
Largest producer of insulin in the world. Diabetes is one of the fastest-growing diseases. Will continue to do well.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$82.63

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Jun 07, 2021
A long time favourite. Recent news was FDA approval of a diabetes drug that can also be used for weight-loss. (Analysts’ price target is $76.50)
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$81.21

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Feb 10, 2021
Take a pill once a week instead of injecting. Big implications moving forward. International sales have gone beyond what US sales were. Good entry point for the next 5-10 years. May get more diversified over time. No debt outstanding. Yield is 1.45% (Analysts’ price target is $75.73)
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$71.22

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novo-Nordisk(NVO)

Oct 20, 2020

It's focused 90% in diabetes products which offers a competitive advantage. He owned this before, but sold it because its options liquidity is low in the US (he trades options). Instead, he owns its direct competitor, Eli Lily, which boasts more product diversity. (Both companies have phase 3 Covid drugs.) Novo is a leader in diabetes and good to own unless you trade options.

Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$71.48

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Sep 14, 2020
The largest maker of insulin in the world. They have a strong diabetes franchise. Type diabetes is growing incredibly quickly around the world. They are one of the few companies that are involved in Diabetes. He thinks it will continue to accelerate and why this one will do well. It is a great story at 21 times earnings and 2% dividend yield. He will continue to buy it.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$66.73

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Aug 25, 2020
If The Democrats Their goal is to sell outside the U.S. which they have done successfully, which have increased revenues, profits and dividends. Most importantly, their pill will replace people with type 2 diabetes from injecting insulin and helps people lose weight. They are the biggest insulin-maker in the world. This will be a big mover in coming years in pharma. You can take profits if the stock has moved up and is outsized in your portfolio.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$66.30

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Aug 20, 2020
(A Top Pick Sep 26/19, Up 29%) Diabetes and hemophilia. Diabetes continues to grow. NVO is at the sweet spot of that. Obesity will become a bigger and bigger issue.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$66.44

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Jul 21, 2020
(A Top Pick Aug 15/19, Up 38%) The biggest producer of insulin in the world. Type 2 diabetes is rapidly growing which helps NVO's growth. Very well-run. They have an obesity drug. A great demographic story. He continues to like it. He'd buy it here.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$68.77

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Novo-Nordisk(NVO)

Feb 07, 2020
International sales were up 11% and US at 1% due to pricing issues there. They are picking up market shares which gives them pricing power and allows them to go into India and China to earn higher margins. Getting out of the US is important for them. Once you get a moat around their product, the oral insulin pill and weight loss, it's smooth sailing. He's owned this since 1995. There are periods they struggle but over time, it's a gift that keeps giving. With the number of diabetics growing around the world, they will have good demand for its products. Right now, he would pause but he would have it in your portfolio.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$63.25

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 106 to 120 of 202 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically